Logo - springer
Slogan - springer

Biomedical Sciences - Pharmacology & Toxicology | FDA Bioequivalence Standards

FDA Bioequivalence Standards

Yu, Lawrence X., Li, Bing V. (Eds.)

2014, XIII, 465 p. 58 illus., 26 illus. in color.

Available Formats:
eBook
Information

Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.

You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.

After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.

 
$159.00

(net) price for USA

ISBN 978-1-4939-1252-0

digitally watermarked, no DRM

Included Format: PDF and EPUB

download immediately after purchase


learn more about Springer eBooks

add to marked items

Hardcover
Information

Hardcover version

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.

 
$209.00

(net) price for USA

ISBN 978-1-4939-1251-3

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days


add to marked items

  • Covers the fundamentals as well as the most up-to-date progress in bioequivalence standards, which are critical to new and generic development and regulation
  • Discusses the current best practices in bioanalytical method validation and conduct, introduces recent developments in bioanalysis, and highlights the challenges in bioanalysis
  • Introduces FDA approaches for highly variable drugs, the partial AUC concept, and narrow therapeutic index drugs

This comprehensive reference provides an in-depth discussion on state-of-the-art regulatory science in bioequivalence. In sixteen chapters, the volume explores a broad range of topics pertaining to bioequivalence, including its origin and principles, statistical considerations, food effect studies, conditions for waivers of bioequivalence studies, Biopharmaceutics Classification Systems, Biopharmaceutics Drug Disposition Classification System, bioequivalence modeling/simulation, and best practices in bioanalysis. It also discusses bioequivalence studies with pharmacodynamic and clinical endpoints as well as bioequivalence approaches for highly variable drugs, narrow therapeutic index drugs, liposomes, locally acting gastrointestinal drug products, topical products, and nasal and inhalation products.

FDA Bioequivalence Standards is written by FDA regulatory scientists who develop regulatory policies and conduct regulatory assessment of bioequivalence. As such, both practical case studies and fundamental science are highlighted in these chapters. The book is a valuable resource for scientists who work in the pharmaceutical industry, regulatory agencies, and academia as well as undergraduate and graduate students looking to expand their knowledge about bioequivalence standards.

Content Level » Research

Keywords » ANDA - bioequivalence - narrow therapeutic window index drugs - regulations - simulation

Related subjects » Pharmacology & Toxicology

Table of contents / Preface / Sample pages 

Popular Content within this publication 

 

Articles

Read this Book on Springerlink

Services for this book

New Book Alert

Get alerted on new Springer publications in the subject area of Pharmaceutical Sciences / Technology.